Theratechnologies to Present at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5GlobeNewsWire • 09/30/20
Theratechnologies Announces Preliminary Third-Quarter Fiscal 2020 Financial ResultsGlobeNewsWire • 09/21/20
Theratechnologies to Develop Tesamorelin for the Treatment of NASH in the General PopulationGlobeNewsWire • 09/10/20
Theratechnologies to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020GlobeNewsWire • 07/30/20
Theratechnologies NASH Data And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 07/26/20
Theratechnologies Inc. (THTX) CEO Paul Lévesque on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 07/15/20
Theratechnologies Announces Financial Results for the Second Quarter of Fiscal 2020GlobeNewsWire • 07/15/20
New Data Show Theratechnologies’ SORT1+ Technology is Effective in Many Treatment-Resistant CancersGlobeNewsWire • 06/22/20
Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive CancersGlobeNewsWire • 05/15/20
Theratechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/16/20
Theratechnologies Inc. (THTX) CEO Paul Lévesque on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 04/14/20
Visceral Fat is a Predictor of Liver Fibrosis and Fibrosis Progression in People Living With HIVGlobeNewsWire • 03/11/20
Theratechnologies Inc. (THTX) CEO Luc Tanguay on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/25/20
Theratechnologies Signs Agreements With Massachusetts General Hospital and Dr. Steven GrinspoonGlobeNewsWire • 02/04/20
Theratechnologies Issues Preliminary Revenue Estimates for Fiscal Year 2019 and Revenue Guidance for Fiscal Year 2020GlobeNewsWire • 12/19/19